153 related articles for article (PubMed ID: 26168498)
21. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
[TBL] [Abstract][Full Text] [Related]
22. Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets.
Kang S; Xie J; Ma S; Liao W; Zhang J; Luo R
Immunobiology; 2010; 215(2):153-62. PubMed ID: 19450895
[TBL] [Abstract][Full Text] [Related]
23. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
24. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
[TBL] [Abstract][Full Text] [Related]
25. Differential survival of γδT cells, αβT cells and NK cells upon engagement of NKG2D by NKG2DL-expressing leukemic cells.
Poggi A; Zancolli M; Boero S; Catellani S; Musso A; Zocchi MR
Int J Cancer; 2011 Jul; 129(2):387-96. PubMed ID: 20853320
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells.
Nicol AJ; Tazbirkova A; Nieda M
Clin Cancer Res; 2011 Aug; 17(15):5140-51. PubMed ID: 21653690
[TBL] [Abstract][Full Text] [Related]
27. Increased prevalence of IL-17-producing peripheral blood lymphocytes in pre-eclampsia.
Toldi G; Rigó J; Stenczer B; Vásárhelyi B; Molvarec A
Am J Reprod Immunol; 2011 Sep; 66(3):223-9. PubMed ID: 21306467
[TBL] [Abstract][Full Text] [Related]
28. Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy.
Sanvito L; Makowska A; Gregson N; Nemni R; Hughes RA
Autoimmunity; 2009; 42(8):667-77. PubMed ID: 19886739
[TBL] [Abstract][Full Text] [Related]
29. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination.
Correll A; Tuettenberg A; Becker C; Jonuleit H
Exp Dermatol; 2010 Aug; 19(8):e213-21. PubMed ID: 20500773
[TBL] [Abstract][Full Text] [Related]
30. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
Rolinski J; Hus I
J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
[TBL] [Abstract][Full Text] [Related]
31. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O
Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
[TBL] [Abstract][Full Text] [Related]
33. Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation.
Karnell FG; Lin D; Motley S; Duhen T; Lim N; Campbell DJ; Turka LA; Maecker HT; Harris KM
Clin Exp Immunol; 2017 Sep; 189(3):268-278. PubMed ID: 28498568
[TBL] [Abstract][Full Text] [Related]
34. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
35. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
Soleimani A; Berntsen A; Svane IM; Pedersen AE
Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
[TBL] [Abstract][Full Text] [Related]
36. Whole blood interferon-γ levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer.
Ishikawa T; Kokura S; Sakamoto N; Okayama T; Endo M; Tsuchiya R; Okajima M; Matsuyama T; Adachi S; Kamada K; Katada K; Uchiyama K; Handa O; Takagi T; Yagi N; Ando T; Uno K; Naito Y; Yoshikawa T
Int J Cancer; 2013 Sep; 133(5):1119-25. PubMed ID: 23420507
[TBL] [Abstract][Full Text] [Related]
37. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.
Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD
J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907
[TBL] [Abstract][Full Text] [Related]
38. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
39. Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine.
Gustafsson K; Ingelsten M; Bergqvist L; Nyström J; Andersson B; Karlsson-Parra A
Cancer Res; 2008 Jul; 68(14):5965-71. PubMed ID: 18632652
[TBL] [Abstract][Full Text] [Related]
40. Increase of regulatory T cells in the peripheral blood of cancer patients.
Wolf AM; Wolf D; Steurer M; Gastl G; Gunsilius E; Grubeck-Loebenstein B
Clin Cancer Res; 2003 Feb; 9(2):606-12. PubMed ID: 12576425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]